search
Back to results

Impact of Web Application Support Versus Standard Management on Compliance With Adjuvant Hormone Therapy at 18 Months in Patients Treated for Breast Cancer (WEBAPPAC)

Primary Purpose

Web-application, Breast Cancer, Hormono Therapy

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
WEB-Application
Standard accompaniment
Sponsored by
Centre Francois Baclesse
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Web-application

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient > 18 years old
  • Breast cancer patient candidate for adjuvant hormone therapy
  • Mastery of the French language
  • Patient with a cell phone and an Internet connection
  • Patient able to use a computer, smartphone, or tablet.
  • Patient affiliated to a social security system
  • Signing of informed consent prior to any specific study-related procedure

Exclusion Criteria:

  • Patient who has previously received hormone therapy for cancer.
  • Patient not trained in the use of the application
  • Any associated medical or psychiatric condition that might compromise the patient's ability to participate in the study
  • Patients with locoregional or metastatic recurrence
  • Other history of cancer.
  • Patient deprived of liberty, under guardianship or curatorship
  • Simultaneous participation in a therapeutic clinical trial or other clinical study involving a connected tool
  • Patient unable to undergo trial follow-up for geographical, social or psychopathological reasons

Sites / Locations

  • Centre François baclesseRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

WEB-application

Standard accompaniment

Arm Description

Outcomes

Primary Outcome Measures

Observance of hormontherapy
Evaluate the benefit of a web-based application on hormone therapy compliance (Morisky questionnary; answer Yes or No; 8 questions)

Secondary Outcome Measures

Quality of life with self questionnaires
Quality of life scores according (EORTC QLQ-C30 self-questionnaires ; minimum not at all to maximum Lot; 30 questions)
Quality of life with self questionnaires
uality of life scores according (EORTC QLQ-BR23 self-questionnaires ; minimum not at all to maximum Lot; 23 questions)

Full Information

First Posted
September 14, 2020
Last Updated
July 31, 2023
Sponsor
Centre Francois Baclesse
search

1. Study Identification

Unique Protocol Identification Number
NCT04554927
Brief Title
Impact of Web Application Support Versus Standard Management on Compliance With Adjuvant Hormone Therapy at 18 Months in Patients Treated for Breast Cancer
Acronym
WEBAPPAC
Official Title
Impact of Web Application Support Versus Standard Management on Compliance With Adjuvant Hormone Therapy at 18 Months in Patients Treated for Breast Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 3, 2020 (Actual)
Primary Completion Date
September 3, 2023 (Anticipated)
Study Completion Date
March 3, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Francois Baclesse

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The investigators hypothesize that the implementation of a Web-application in patients initiating adjuvant hormone therapy for breast cancer brings a benefit on treatment adherence and quality of life.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Web-application, Breast Cancer, Hormono Therapy

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
438 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
WEB-application
Arm Type
Experimental
Arm Title
Standard accompaniment
Arm Type
Active Comparator
Intervention Type
Other
Intervention Name(s)
WEB-Application
Intervention Description
The patients of the Web-application arm will be trained on the devices and the application will be installed either on their smartphone or on another support (computer, tablet).
Intervention Type
Other
Intervention Name(s)
Standard accompaniment
Intervention Description
Personalized schedule of medical follow-up given to the patient
Primary Outcome Measure Information:
Title
Observance of hormontherapy
Description
Evaluate the benefit of a web-based application on hormone therapy compliance (Morisky questionnary; answer Yes or No; 8 questions)
Time Frame
18 months
Secondary Outcome Measure Information:
Title
Quality of life with self questionnaires
Description
Quality of life scores according (EORTC QLQ-C30 self-questionnaires ; minimum not at all to maximum Lot; 30 questions)
Time Frame
18 months
Title
Quality of life with self questionnaires
Description
uality of life scores according (EORTC QLQ-BR23 self-questionnaires ; minimum not at all to maximum Lot; 23 questions)
Time Frame
18 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient > 18 years old Breast cancer patient candidate for adjuvant hormone therapy Mastery of the French language Patient with a cell phone and an Internet connection Patient able to use a computer, smartphone, or tablet. Patient affiliated to a social security system Signing of informed consent prior to any specific study-related procedure Exclusion Criteria: Patient who has previously received hormone therapy for cancer. Patient not trained in the use of the application Any associated medical or psychiatric condition that might compromise the patient's ability to participate in the study Patients with locoregional or metastatic recurrence Other history of cancer. Patient deprived of liberty, under guardianship or curatorship Simultaneous participation in a therapeutic clinical trial or other clinical study involving a connected tool Patient unable to undergo trial follow-up for geographical, social or psychopathological reasons
Facility Information:
Facility Name
Centre François baclesse
City
Caen
ZIP/Postal Code
14000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
François GERNIER, Study nurse
Phone
+ 33 2 31 45 50 50
Email
f.gernier@baclesse.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Jean-Michel GRELLARD, project manager
Phone
+ 33 2 31 45 50 50
Email
jm.grellard@baclesse.unicancer.fr
First Name & Middle Initial & Last Name & Degree
François GERNIER, Study nurse
First Name & Middle Initial & Last Name & Degree
Gaelle ANNE, Study nurse
First Name & Middle Initial & Last Name & Degree
Charlotte CEINTRE, Study nurse
First Name & Middle Initial & Last Name & Degree
Rose-Marie CHARLES, Study nurse
First Name & Middle Initial & Last Name & Degree
Audrey FAVEYRIAL, MD
First Name & Middle Initial & Last Name & Degree
Christelle LEVY, MD
First Name & Middle Initial & Last Name & Degree
Emile GEORGE, MD
First Name & Middle Initial & Last Name & Degree
Djelila ALLOUACHE, MD
First Name & Middle Initial & Last Name & Degree
Julien GEFFRELOT, MD
First Name & Middle Initial & Last Name & Degree
Carine SEGURA, MD
First Name & Middle Initial & Last Name & Degree
Katharina GUNZER, MD
First Name & Middle Initial & Last Name & Degree
Ioana HRAB, MD
First Name & Middle Initial & Last Name & Degree
Alison JOHNSON, MD
First Name & Middle Initial & Last Name & Degree
Adeline MOREL, MD

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Impact of Web Application Support Versus Standard Management on Compliance With Adjuvant Hormone Therapy at 18 Months in Patients Treated for Breast Cancer

We'll reach out to this number within 24 hrs